Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJPS (1) Genet. Mol. Biol. (1) Autor Anuganti,Haripriya (1) Anumolu,Panikumar Durga (1) Lizcano,Fernando (1) Neeli,Sirisha (1) Ranganatham,Sathesh Babu Puvvadi (1) Satya,Subrahmanyam Chavali Venkata (1) Vargas,Diana (1) Mais... Palavra-chave Telmisartan (2) Amlodipine besylate (1) Combined dosage forms/quality control (1) DNA binding proteins co-activator (1) Dissolution test/combined dosage forms (1) Gene expression (1) Spectrofluorimetry/quantification analysis (1) Transcription (1) Mais... Tipo do documento Info:eu-repo/semantics/article (2) Ano 2014 (1) 2013 (1) País Brazil (2) Idioma Inglês (2)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 2 Primeira ... 1 ... Última Development of dissolution test method for a telmisartan/amlodipine besylate combination using synchronous derivative spectrofluorimetry BJPS Anumolu,Panikumar Durga; Neeli,Sirisha; Anuganti,Haripriya; Ranganatham,Sathesh Babu Puvvadi; Satya,Subrahmanyam Chavali Venkata. The dissolution process is considered an important in vitro tool to evaluate product quality and drug release behavior. Single dissolution methods for the analysis of combined dosage forms are preferred to simplify quality control testing. The objective of the present work was to develop and validate a single dissolution test for a telmisartan (TEL) and amlodipine besylate (AML) combined tablet dosage form. The sink conditions, stability and specificity of both drugs in different dissolution media were tested to choose a discriminatory dissolution method, which uses an USP type-II apparatus with a paddle rotating at 75 rpm, with 900 mL of simulated gastric fluid (SGF without enzymes) as the dissolution medium. This dissolution methodology provided good... Tipo: Info:eu-repo/semantics/article Palavras-chave: Combined dosage forms/quality control; Dissolution test/combined dosage forms; Telmisartan; Amlodipine besylate; Spectrofluorimetry/quantification analysis. Ano: 2014 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502014000200329 Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism Genet. Mol. Biol. Lizcano,Fernando; Vargas,Diana. The PPARγ nuclear receptor regulates the expression of genes involved in lipid and carbohydrate metabolism, and it has protective effects in some patients with type 2 diabetes. Nevertheless, the therapeutic value of the PPARγ nuclear receptor protein is limited due to the secondary effects of some PPARγ ligands. Because the downstream effects of PPARγ are determined by the binding of specific cofactors that are mediated by ligand-induced conformational changes, we evaluated the differential effects of various ligands on the binding of certain cofactors associated with PPARγ. The ligands used were rosiglitazone for treating type 2 diabetes and telmisartan for treating arterial hypertension. Functional, phenotypic, and molecular studies were conducted on... Tipo: Info:eu-repo/semantics/article Palavras-chave: DNA binding proteins co-activator; Gene expression; Transcription; Telmisartan. Ano: 2013 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1415-47572013000100020 Registros recuperados: 2 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco